Gene Editing Stocks Caribou and Verve Show Early Promise in Treating Lymphoma and High Cholesterol
-
Caribou Biosciences is developing a gene-edited cell therapy, CB-010, to treat lymphoma that has shown promise in early trials and has regulatory support to speed development.
-
Verve Therapeutics is using gene editing to try to permanently cure high cholesterol, with data so far showing LDL cholesterol declines of up to 55% from one treatment.
-
Both companies have enough cash to fund operations for the next 2+ years without needing to raise additional capital.
-
The gene editing approaches both companies are taking could eventually be applied to treat a wider range of diseases beyond the initial targets.
-
While still highly risky given the early stage, Caribou and Verve represent intriguing gene editing stocks to consider as the biotech sector rebounds.